Viewing StudyNCT00236548



Ignite Creation Date: 2024-05-05 @ 12:05 PM
Last Modification Date: 2024-10-26 @ 9:20 AM
Study NCT ID: NCT00236548
Status: COMPLETED
Last Update Posted: 2011-05-18
First Post: 2005-10-07

Brief Title: Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
Sponsor:
Organization: Johnson Johnson Pharmaceutical Research Development LLC

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 1
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE3
Observational Models:
Time Perspective List:
Who Masked List: